A Constant State of Liveliness

A driving force behind the collaboration between Ullern Upper Secondary School and Oslo Cancer Cluster is stepping down. This is her adventure.

After fifteen great and productive years at Ullern Upper Secondary School, Esther Eriksen steps down from her position as vice principle in the upcoming month. Esther, who has been responsible for many various tasks in her position, has been a part of Ullern’s transformative experience alongside Oslo Cancer Cluster’s emergence in 2009 and recounts her time at Ullern.

A flourish of innovation
Esther Eriksen describes the transformation and unification of Ullern Upper Secondary School and Oslo Cancer Cluster as being a progression from a strong belief in it’s potential to a flourish of innovation.

The collaboration has become a constant state of liveliness: from pupils attending classes, to research, to teamwork and a continuous process of growth.

Since 2009, the school and the cluster, with all its member companies and institutions, has unified to produce a collaborative arena for the pupils. This is an experience Eriksen describes nothing short of “wonderful, educational and groundbreaking”.

Diversity in teamwork
– The collaborative experience is incredible due to the pupils’ ability to take in experience in regards to teamwork. Not to mention they learn how knowledge from books can be translated to hands on work and ultimately get a feel for what life has in store for them, says Eriksen.

Esther Eriksen describes her own experience as being much of the same, and stresses the notion of working as a team.

– Diversity in teamwork is really important! We see this from well-received results and happy pupils, says Eriksen.

Future potential
In regards to the future of this collaboration, Vice Principle Eriksen expresses her desire to see the school continue down the path it has set out on. She wants to see the pupils continue to learn, gain opportunities and continue to work collaboratively.

– I wish the pupils would gain further awareness of the potential this unification brings, and hope to see increased interest in teamwork as an integrity.

The best of moments
Esther Eriksen also shares what she would consider the best moments of her time at Ullern, of which these were her favorite:

  1. When the new school first opened in the Oslo Cancer Cluster Innovation Park in 2015 – hard work finally turned to fruition
  2. Seeing how happy and motivated the pupils are when they do projects with scientists, businesses and hospitals in the cluster
  3. The emergence of vocational studies, such as electronics and health care studies, at Ullern Upper Secondary School

To conclude, Vice Principle Eriksen would like to leave the school and her colleagues this message: that she will continue to observe and follow the thriving development taking place at Ullern Upper Secondary School.

– This is only the beginning!

 

ICCS 2014: Cutting-edge oncology innovations

International Cancer Cluster Showcase San Diego 2014

On June 22nd, one day prior to the BIO International Convention in San Diego, the International Cancer Cluster Showcase 2014 kicks off. The showcase is an opportunity to head-start the partnering at BIO 2014 and get the latest on what is going on in the cancer clusters of Oslo, Massachusetts, Quebec, Chicago, Toulouse, and the UK Golden Triangle.

For the 3rd time Oslo Cancer Cluster will present cutting edge innovations together with its international partners from North America and Europe. Oslo Cancer Cluster members selected to present at this year’s International Cancer Cluster Showcase (ICCS) are BerGenBio, PCI Biotech and Nextera.


ICCS – A winning concept

Previous ICCS-events have attracted 150 – 200 dedicated international oncology professionals. Positive feedback has encouraged Oslo Cancer Cluster and its international partners to continue with this meeting format. BerGenBio’s CEO Richard Godfrey says:

“The ICCS was a great start to BIO 2013, it was interesting to see the other cancer companies present and we made a few excellent contacts that otherwise we may not have connected with. I will certainly be present at ICCS 2014.”

This year two new partners, namely Cancer Campus from Villejuif and Stockholm-Uppsala Life Sciences are joining the ICCS and contribute to leverage the portfolio of oncology partnering opportunities. The International Cancer Cluster Showcase 2014 will be hosted at the San Diego Convention Centre, same site as the BIO 2014 will be hosted.

For information on presenting companies and registration, please see the ICCS conference website: www.internationalcancercluster.org.

 

BIO International Convention 23-26 June, 2014
Oslo Cancer Cluster will also be represented at the world’s largest biotech conference, BIO International Convention. This year the event is taking place on 23-26 June in San Diego, California at the San Diego Convention Center.

Oslo Cancer Cluster will share a centrally located booth with the other Nordic regions; Medicon Valley Alliance, Biopeople, Invest in Skåne and Copenhagen Capacity. All Oslo Cancer Cluster members may display material at the booth which will function as a central meeting place for the members, coordinated by the Oslo Cancer Cluster team.

Building strong international networks to stimulate collaboration, partnerships and thereby innovation for our members is a key strategic goal for Oslo Cancer Cluster. Read more here.

More information about BIO 2014 is found at convention.bio.org.

Excellent evaluation of Oslo Cancer Cluster

Tone Ikdahl at the Oslo University Hospital

The six year evaluation of Oslo Cancer Cluster as a Norwegian Centre of Expertise concludes that Oslo Cancer Cluster is a strong biotech cluster, well positioned within the global oncology industry. “This plays well with our ambition to take the step up a level and become a Global Centre of Excellence,” says Jónas Einarsson, acting CEO of Oslo Cancer Cluster.

The thorough evaluation report gives a comprehensive picture of the Oslo Cancer Cluster as of today; our projects and plans and also our achievements over the last three years since our first evaluation in 2010. Both evaluations have been done by Oxford Research.

Evaluation of Oslo Cancer Cluster NCE after 6 years.
Evaluation of Oslo Cancer Cluster NCE after 3 years.


Bottlenecks have been identified and reduced

“The evaluation points out that Oslo Cancer Cluster from 2010-2013 have managed to address the challenges for oncology R&D in Norway as well as the weaker points from the first evaluation. We have identified some crucial bottlenecks within clinical trials, and contributed to reduce the pre-clinical development time for oncology start-ups. We have also made it easier for SME`s to attract the capital they need to develop new oncology treatment. This I am very proud of”, says Jónas Einarsson, acting CEO of Oslo Cancer Cluster.

Einarsson continues: “All in all we have received an excellent evaluation. The evaluation concludes that we have untapped innovation potential, and that we need to address this issue in the years to come. This is totally in line with what we plan to do through the work with the Oslo Cancer Cluster Innovation Park and the Oslo Cancer Cluster Incubator.”


Well positioned to become a Global Centre of Expertise

The public cluster program in Norway has until now included two levels; Arena and Norwegian Centre of Expertise. In 2014 a third and higher level, the Global Centre of Expertise (GCE) will be introduced. Only mature clusters with a global position will obtain the elite status as a GCE and probably only 4-5 clusters will be chosen.

“Oslo Cancer Cluster`s ambition is to become one of these 4-5 GCE-clusters. The evaluation shows that we are a global player in the oncology field, and that we have succeeded in establishing an extensive international network that exposes the members for the global oncology industry and secures that recourses like capital and competence are accessible,” says Einarsson.

Einarsson points out that the three years to come will take the cluster a giant step further on the global scale with a targeted focus on innovation: “In 2015 Oslo Cancer Cluster Innovation Park opens and this will become a power centre for oncology R&D. The Oslo Cancer Cluster Incubator will make sure that we have new commercialization’s from oncology research. These new start-ups will have better frame work conditions to succeed than ever before. Oslo Cancer Cluster has since the start managed to build a solid fundament. In many ways the cluster has just begun its work.”


Other conclusions from the evaluation:

  • Particularly strong topics within Oslo Cancer Cluster are personalised medicine and immuno-oncology. These are also the buzzwords on the global oncology scene, which makes the cluster well positioned and attractive as a collaborative partner.
  • The cluster have increased the number of members considerably and in parallel developed into a national cluster representing the entire oncology-value chain from bench to bedside.
  • There is now a considerably degree of trust between the members which is based on regular networking and collaboration across disciplines.
  • The strategy work performed during this three-year period have been of good quality and have been embedded in a god way.
  • The feedback from the members on the importance of Oslo Cancer Cluster for their company, institution is to some extent a bit weaker in 2013 than 2010. We take this very seriously and will take action and see how we may perform better here.